Demographic, clinical characteristics of participants and association with saphenous vein graft disease (SVGD)
| Variable | Participants with SVGD (n=124) | Participants without SVGD (n=107) | P values |
| Age (years) | 65.0±8.5 | 66.2±7.9 | 0.26 |
| Male, n (%) | 100 (81.3) | 86 (80.4) | 0.86 |
| BMI (kg/m2) | 25.3±4.1 | 27.3±1.9 | 0.15 |
| CABG age (years) | 56.9±9.1 | 60.2±8.0 | <0.01 |
| Time from CABG surgery (years) | 8.1±3.8 | 6.1±3.7 | <0.01 |
| Family history of cardiovascular disease, n (%) | 37 (29.8) | 13 (12.2) | <0.01 |
| Hypertension, n (%) | 92 (74.2) | 68 (63.6) | 0.08 |
| Diabetes mellitus, n (%) | 52 (41.9) | 53 (49.5) | 0.25 |
| Hypercholesterolaemia, n (%) | 86 (69.4) | 67 (62.6) | 0.28 |
| History of stroke, n (%) | 22 (17.7) | 13 (12.1) | 0.24 |
| Current smoking, n (%) | 71 (57.3) | 45 (42.1) | 0.02 |
| Current alcohol drinking, n (%) | 38 (30.7) | 29 (27.1) | 0.55 |
| Cardiac function (NYHA classes), n (%) | |||
| I–II | 102 (82.3) | 82 (76.6) | 0.29 |
| III–IV | 22 (17.7) | 25 (23.4) | |
| Ischaemia type, n (%) | |||
| Stable angina | 18 (14.5) | 31 (29.0) | <0.01 |
| Acute coronary syndrome | 106 (85.5) | 76 (71.0) | |
| Native lesion vessel number | |||
| 1 | 1 (0.8) | 6 (5.6) | 0.04 |
| 2 | 29 (23.6) | 33 (30.8) | |
| 3 | 93 (75.6) | 68 (63.6) | |
| Progression of native vessels, n (%) | 120 (96.8) | 98 (91.6) | 0.09 |
| Number of SVG (mean) | 2.7±0.7 | 2.6±0.7 | 0.08 |
| Graft types | |||
| SVG-LAD, n (%) | 35 (34.0) | 35 (58.3) | <0.01 |
| SVG-RCA, n (%) | 31 (29.8) | 13 (27.1) | 0.73 |
| SVG-LCX, n (%) | 25 (23.8) | 16 (30.2) | 0.39 |
| SVG-Diag, n (%) | 37 (33.9) | 29 (49.2) | 0.05 |
| LAD-PDA, n (%) | 70 (59.8) | 66 (77.7) | <0.01 |
| LCX-OM, n(%) | 51 (45.5) | 38 (61.3) | 0.04 |
| Stenosis degree of SVG | |||
| SVG-LAD | 67.1±43.4 | 5.8±3.6 | <0.01 |
| SVG-RCA | 78.4±39.5 | 7.5±3.1 | <0.01 |
| SVG-LCX | 70.5±40.9 | 6.0±3.4 | <0.01 |
| SVG-Diag | 66.4±47.1 | 13.2±3.5 | <0.01 |
| SVG-PDA | 68.5±40.3 | 14.1±3.0 | <0.01 |
| SVG-OM | 74.5±38.0 | 17.5±4.2 | <0.01 |
| Ejection fraction, n (%) | 54.2±9.1 | 55.8±8.2 | 0.19 |
| LVEDD (mm) | 53.1±5.7 | 50.9±7.3 | 0.01 |
| Drug usage, n (%) | |||
| Aspirin, n (%) | 118 (95.2) | 102 (95.3) | 0.85 |
| β-Blocker, n (%) | 87 (70.2) | 83 (77.6) | 0.52 |
| Statin, n (%) | 94 (75.8) | 78 (72.9) | 0.73 |
| ACE/ARB, n (%) | 84 (67.7) | 71 (66.4) | 0.70 |
| Clopidogrel, n (%) | 62 (50.0) | 65 (60.7) | 0.10 |
BMI, body mass index; CABG, coronary artery bypass grafting; LAD, left anterior descend; LCX, left circumflex artery; LVEDD, left ventricular end-diastolic diameter; NYHA, New York Heart Association; OM, obtuse marginal branch; PDA, posterior descend artery; RCA, right coronary artery; UA, uric acid.